Product
Lucentis
Aliases
ranibizumab, Ranibizumab, Reference Product
6 clinical trials
8 indications
Indication
Age-Related Macular DegenerationIndication
Age-related macular degenerationIndication
Age-related Macular DegenerationIndication
Diabetic Macular EdemaIndication
Diabetic RetinopathyIndication
Macular EdemaIndication
Retinal DiseaseIndication
retinal degenerationClinical trial
A Phase 2A Randomized Open-Label Controlled Trial to Assess the Safety of Zimura™ (Anti-C5 Aptamer) Administered in Combination With Anti-VEGF Therapy in Treatment Experienced Patients With Neovascular Age-Related Macular DegenerationStatus: Terminated, Estimated PCD: 2018-04-24
Clinical trial
A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular DegenerationStatus: Completed, Estimated PCD: 2012-06-01
Clinical trial
A Phase 2A Open-label Trial to Assess the Safety of ZIMURA™ (Anti-C5) Administered in Combination With LUCENTIS® 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular DegenerationStatus: Completed, Estimated PCD: 2018-10-18
Clinical trial
Randomized, Double-blind, Parallel, Active Controlled Study to Compare Efficacy & Safety Between Ranibizumab 10mg/ml Injection of Incepta and Lucentis in Patients With Diabetic Macular Edema by ITV InjectionStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Multicenter, Randomized, Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of BAT5906 and Ranibizumab (Lucentis®) in Patients With Neovascular Age-related Macular DegenerationStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Randomized, Active-controlled, Patient and Investigator-masked, Multiple Dose Proof-of-concept Study of Intravitreal LKA651 in Patients With Diabetic Macular EdemaStatus: Completed, Estimated PCD: 2022-06-17